Company · CIK 1714899
Denali Therapeutics Inc.
| CIK | 1714899 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
| Business address | CA |
| Listed | DNLI (Nasdaq) |
| First annual or quarterly report | 2018-03-19 |
Offerings
5 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-285326 | 2025-02-27 | 2025-12-10 | 3 | |
| 333-278174 | 2024-03-22 | 2024-03-22 | 1 | |
| 333-263107 | 2022-02-28 | 2022-10-20 | 3 | |
| 333-230232 | 2019-03-12 | 2020-01-29 | 3 | |
| 333-221522 | 2017-11-13 | 2017-12-08 | 5 |
Filings
16| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2025-12-10 | 424B5Shelf takedown | 333-285326 | 0001628280-25-056361 |
| 2025-12-09 | 424B5Shelf takedown | 333-285326 | 0001628280-25-056085 |
| 2025-02-27 | S-3ASRShelf registered | 333-285326 | 0001628280-25-008647 |
| 2024-03-22 | S-3ASRShelf registered | 333-278174 | 0001714899-24-000096 |
| 2022-10-20 | 424B5Shelf takedown | 333-263107 | 0001628280-22-026763 |
| 2022-10-18 | 424B5Shelf takedown | 333-263107 | 0001628280-22-026571 |
| 2022-02-28 | S-3ASRShelf registered | 333-263107 | 0001628280-22-004297 |
| 2020-01-29 | 424B5Shelf takedown | 333-230232 | 0001628280-20-000680 |
| 2020-01-27 | 424B5Shelf takedown | 333-230232 | 0001628280-20-000564 |
| 2019-03-12 | S-3ASRShelf registered | 333-230232 | 0001714899-19-000018 |
| 2017-12-08 | 424B4Final prospectus | 333-221522 | 0001193125-17-364327 |
| 2017-12-07 | EFFECTDeclared effective | 333-221522 | 9999999995-17-003174 |
| 2017-12-07 | S-1/AAmendment | 333-221522 | 0001193125-17-363254 |
| 2017-11-27 | S-1/AAmendment | 333-221522 | 0001193125-17-351618 |
| 2017-11-13 | S-1Registration filed | 333-221522 | 0001193125-17-340997 |
| 2017-09-08 | DRSDraft made public | 377-01709 | 0000950123-17-008432 |